TARSONS Q1 FY27 Guidance vs Delivery (TARSONS Management Mirror)

Consolidated Q1 FY27 Revenue Reported at INR 110.2 Crore; FY27 Growth Guided at 15% or Higher Amid Favorable Domestic Momentum

In the Dec'25 Qtr concall, management anticipated stronger revenue growth in FY27 and beyond, driven by new cell culture capacities at the Panchla facility, with exports seen as the primary growth engine. In the Mar'26 Qtr concall, management maintained expectations for operating leverage to aid operational performance starting in FY27, despite Q4 FY26 exports declining 13.4% due to Middle East geopolitical disruptions. In the Jun'26 Qtr results, the company reported Q1 FY27 consolidated revenue of INR 110.2 crores (a 20.7% YoY growth). During the Jun'26 Qtr concall, management noted a meaningful revival in domestic demand (returning to pre-COVID 8% to 9% growth rates) and export order recoveries. Management stated they remain optimistic about achieving a 15% or higher sustainable revenue growth rate in FY27 and beyond, contingent on external international conditions and new product launch success.